Insilico Medicine and the Emirates Drug Establishment announced ISM0387 on April 23, the first drug candidate to be discovered, optimized, and nominated entirely inside the UAE. ISM0387 is an MTA-cooperative PRMT5 inhibitor — a novel scaffold designed to cross the blood-brain barrier and treat glioblastoma, an aggressive and largely untreatable brain cancer. Insilico's team in Masdar City screened 90 AI-generated candidates through its Chemistry42 platform, completed lead discovery in six months, and reached preclinical nomination in under a year.
The mechanism matters. PRMT5 has been a difficult drug target because broad inhibition causes serious off-tissue toxicity. The MTA-cooperative approach — making the drug only active in cells with elevated MTA, which is characteristic of certain tumors — is a way to get selectivity that has been hard to achieve with conventional medicinal chemistry. Insilico says ISM0387 shows improved in vitro selectivity, dose-dependent efficacy in disease models, and meaningful CNS penetration.
It is the company's 30th AI-discovered preclinical candidate, and notable as the first one delivered out of its UAE program rather than the larger US-China operations. The broader pipeline of AI-discovered drug programs is now more than 170 in clinical development, with about 15 in pivotal Phase III trials. None has received FDA approval yet — the field is still waiting for its first AI-designed approved drug — but the cycle time from molecule to clinic is collapsing in a way that traditional medicinal chemistry cannot match.
For learners: drug discovery is one of the clearest cases where AI is not replacing scientists but changing the unit of work. The scarce skill is no longer screening compounds by hand — it's knowing which molecular property to optimize for, which assays to run, and how to read what the model proposes. If you are a biology or chemistry student curious about AI, this is the layer where your domain knowledge will pay off the most.